ELIAS Animal Health has been named a 2020 Kansas City Startup to Watch by Startland News. The list of 10 startups is announced by Startland News each year and features innovative, entrepreneurial organizations making waves in the Kansas City area. “This nomination is a reflection of the hard work we’ve put in to bring our cancer immunotherapy to a broader audience,” said Tammie Wahaus, CEO of ELIAS. “I am excited to be included on this list of innovative companies in Kansas City, and look forward to a successful and impactful 2020.” Read the ELIAS Animal Health feature story, or view the full list startups on StartlandNews.com.
Olathe, Kan., June 6, 2019 – ELIAS Animal Health, a clinical stage development company advancing novel treatments for cancer in companion animals, and BodeVet, a Maryland-based company focused on the development of novel blood products for use in veterinary transfusion and regenerative medicine, have announced a joint effort to significantly expand the availability of ELIAS’ ECI® treatment for canine cancer via the mobile apheresis capabilities of BodeVet. Apheresis is a processing procedure that separates blood into different components and, in this case, yields the T cells critical to the ELIAS treatment protocol. Currently, there are twelve locations offering apheresis for pets. BodeVet offers a mobile service that will enable veterinary oncologists in most major cities in the United States to incorporate ECI® into their specialty hospital portfolio of oncology services, expanding beyond chemotherapy and radiation. Working together, ELIAS and BodeVet are committed to promoting animal health and welfare by developing [...]
Olathe, Kan., May 15, 2019 – ELIAS Animal Health, a Kansas City company dedicated to improving the treatment options for companion animals diagnosed with cancer, will be featured on Worldwide Business with kathy ireland®. Distributed internationally as sponsored content, you can view a highlight video below. The full interview will air on the following channels: Americas: Fox Business Network May 19, 2019, 5:30 p.m. EST Europe & Africa: Bloomberg EMEA Saturday, May 18, 2019, 7:30 p.m. GMT Asia: Bloomberg Asia Sunday, May 19, 2019, 10:30 a.m. D.F. and 3:00 p.m. HKT
Immunotherapy treatments are a hot topic in the area of treating human malignancies, which begs the question in the minds of many pet owners whose dogs or cats are diagnosed with cancer: where are these therapies for the four-legged members of the family? There are several barriers to making immunotherapies available in the veterinary space. However, a recent article in Veterinary Practice News by Hans Klingemann, MD, PhD, details some of these challenges and highlights the work being done by ELIAS Animal Health to overcome such barriers. “While patient survival outcomes using traditional cancer therapies such as chemotherapy and radiation have not significantly changed in the past couple of decades, they still remain the proven standard of care used by veterinary oncologists,” said Noe Reyes, Chief Medical Officer for ELIAS. “There is a significant unmet need for safer and more effective therapies to treat cancer. Immunotherapies, including adoptive T cell [...]
The University of Missouri recently shared progress on their work in helping advance ELIAS Animal Health’s treatment for bone cancer in dogs. The canine immunotherapy treatment is now available at MU, as well as at other universities and specialty hospitals across the country. Dr. Jeff Bryan, director of the MU's Comparative Oncology and Epigenetics Laboratory and principal investigator of the clinical trial, said of the treatment, “It’s the first time that dogs with osteosarcoma have experienced prolonged survival without receiving chemotherapy, which is really exciting.” Read the full announcement.